Diligence memo · auto-generated · as of July 2, 2026

Sen-Jam Pharmaceutical Llc

Sen-Jam Pharmaceutical Llc looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Sen-Jam Pharmaceutical Llc operates in Pharmaceuticals, based in HUNTINGTON.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Sen-Jam Pharmaceutical Llc has raised $480K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $3.0M on 2020-01-28.

Most recent recorded round closed around 2023-04-22.

Valuation (modeled)modeled

Provath models Sen-Jam Pharmaceutical Llc at approximately $2.7M (range $165K–$13M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.06× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era. Within the normal band (106% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 19 months.

Last raise 3.2 yr ago; this sector typically re-raises about every 13 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round was 10.2× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 11% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 5% of those peers.

Closest niche peers: Eleison Pharmaceuticals Inc, Telomir Pharmaceuticals, Inc., Drusolv Therapeutics, Inc., TF Tech Ventures, Inc., Thyron Pharmaceuticals, Inc..

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.